ECB Bancorp Inc MD
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unreg istered Sales of Equity Securities and Use of Proceeds
There were no sales of unregistered securities during the period covered by this Report.
On August 10, 2023, the Company announced the commencement of a stock repurchase program to acquire up to 458,762 shares, or 5% of the Company’s then outstanding common stock. Repurchases will be made from time to time depending on market conditions and other factors, and will be conducted through open market or private transactions, through block trades, and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission. There is no guarantee as to the exact number of shares to be repurchased by the Company. The following table sets forth the information regarding the Company's common stock repurchase activities during the three months ended March 31, 2024:
| Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Program | Maximum Number of Shares That May Yet Be Purchased Under the Program | |
|---|---|---|---|---|
| From January 1, 2024 to January 31, 2024 | 23,722 | $13.00 | 23,722 | 245,646 |
| From February 1, 2024 to February 29, 2024 | 10,859 | $12.98 | 10,859 | 234,787 |
| From March 1, 2024 to March 31, 2024 | 13,651 | $12.95 | 13,651 | 221,136 |
| Total | 48,232 | $12.98 | 48,232 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.